Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biofrontera Inc (BFRI)

Biofrontera Inc (BFRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,438
  • Shares Outstanding, K 11,648
  • Annual Sales, $ 37,320 K
  • Annual Income, $ -17,760 K
  • EBIT $ -18 M
  • EBITDA $ -16 M
  • 60-Month Beta 0.61
  • Price/Sales 0.19
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.63
  • Most Recent Earnings $-0.59 on 11/12/25
  • Next Earnings Date 03/19/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.29
  • Number of Estimates 1
  • High Estimate 0.29
  • Low Estimate 0.29
  • Prior Year N/A
  • Growth Rate Est. (year over year) -99.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6505 +19.91%
on 02/09/26
1.0100 -22.77%
on 01/26/26
-0.0445 (-5.40%)
since 01/09/26
3-Month
0.5547 +40.62%
on 12/31/25
1.1300 -30.97%
on 11/11/25
-0.2600 (-25.00%)
since 11/10/25
52-Week
0.5360 +45.52%
on 05/30/25
1.1900 -34.45%
on 11/06/25
-0.3700 (-32.17%)
since 02/10/25

Most Recent Stories

More News
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint

Study findings met its primary endpoint and showed highly statistically significant superiority for Ameluz ® vs. vehicle gel (p

BFRI : 0.7800 (-3.74%)
BFRIW : 0.0634 (+0.63%)
Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth

Fourth quarter results represent highest quarterly revenue in Company’s history Q4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz ® Full year 2025 revenues also expected...

BFRI : 0.7800 (-3.74%)
BFRIW : 0.0634 (+0.63%)
Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026 Data generated will support key regulatory milestones for Ameluz PDT in both indications AK and...

BFRI : 0.7800 (-3.74%)
BFRIW : 0.0634 (+0.63%)
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio

• Ameluz ® and RhodoLED ® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc. • Assignment to Biofrontera...

BFRI : 0.7800 (-3.74%)
BFRIW : 0.0634 (+0.63%)
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities

Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz ® over treatment area of 240 cm 2 Completion of this study marks a key milestone...

BFRI : 0.7800 (-3.74%)
BFRIW : 0.0634 (+0.63%)
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT

sNDA for treatment of sBCC with Ameluz ® -PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025 First Phase 3 PDT study in patients with sBCC in the United States submitted to...

BFRI : 0.7800 (-3.74%)
BFRIW : 0.0634 (+0.63%)
Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update

Conference call will be held today, Thursday, November 13 at 10:00 am ET Woburn, MA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company...

BFRI : 0.7800 (-3.74%)
BFRIW : 0.0634 (+0.63%)
Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025

WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the commercialization of dermatological...

BFRI : 0.7800 (-3.74%)
BFRIW : 0.0634 (+0.63%)
Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG

Biofrontera Inc. acquires full U.S. rights to Ameluz ® and RhodoLED ® , including New Drug Application and associated patents, from former parent Biofrontera AG. New earnout structure reduces payment...

BFRI : 0.7800 (-3.74%)
BFRIW : 0.0634 (+0.63%)
Benchmark Co. Reaffirms Their Buy Rating on Biofrontera (BFRI)

Benchmark Co. analyst Bruce Jackson maintained a Buy rating on Biofrontera today and set a price target of $3.00. The company’s shares closed yesterday at $1.04.Elevate Your Investing Strategy: Take...

BFRI : 0.7800 (-3.74%)

Business Summary

Biofrontera Inc. is a biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on the fields of photodynamic therapy and topical antibiotics. The Company's licensed products focus on the treatment of actinic keratoses,...

See More

Key Turning Points

3rd Resistance Point 0.8400
2nd Resistance Point 0.8200
1st Resistance Point 0.8000
Last Price 0.7800
1st Support Level 0.7600
2nd Support Level 0.7400
3rd Support Level 0.7200

See More

52-Week High 1.1900
Fibonacci 61.8% 0.9402
Fibonacci 50% 0.8630
Fibonacci 38.2% 0.7858
Last Price 0.7800
52-Week Low 0.5360

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar